Thinking about cancer or dealing with cancer risk can be scary or overwhelming, but we believe that receiving information and resources is comforting, empowering, and lifesaving.
Raloxifene is second-generation Selective Estrogen Receptor Modulator (SERM) that is used to block the effects of estrogen in postmenopausal women. Although related, raloxifene has a lower risk for endometrial cancer and blood clots and fewer side effects than tamoxifen. The principal adverse events are hot flushes, blood clots, nausea and weight gain.
To date, no prevention clinical trials have studied tamoxifen or raloxifene specifically in women with BRCA1 or BRCA2 mutations.
High-risk women who wish to consider tamoxifen or raloxifene to lower their risk for breast cancer should discuss the benefits, risks and limitations with their health care providers.